


IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (Currently amended) ~~Use of A~~ method for preventive treatment of Parkinson's disease in a subject, comprising administering to the subject a compound of the general formula **[I]**




wherein:

n = 1 to 5;

R2 is OA;


R3 and R4 are each independently selected from H and OA; with A being selected from H, alkyl, alkoxymethyl or a group



wherein R6 and R7 are independently alkyl or aryl;

R5 is a C1-3 alkyl;

R1 is a group selected from hydrogen, 3-pyridyl, 4-pyridyl, optionally substituted phenyl,




wherein X is selected from S, O or NH;

wherein the compound ~~of formula I~~ is present as a racemate or as a pure


(R)- or (S)-enantiomer; ~~as well as~~ or a physiologically acceptable ~~[[salts]]~~
salt of these compounds, as a medicament for the preventive treatment
of Parkinson's disease said compound.

2. (Currently amended) ~~Use according to claim 1~~ The method of Claim 1,
wherein the ~~preventive treatment is performed on individuals who are~~
subject is an individual selected from the group consisting of
 - (a) individuals without symptoms of Parkinson's disease but with an
increased risk of developing Parkinson's disease; ~~[[or]]~~ and
 - (b) individuals with early symptoms of Parkinson's disease, in whom at
least three of the four cardinal symptoms of Parkinson's disease
(rigidity, resting tremors, bradykinesia, postural instability) are not yet
or are only partially present.
3. (Currently amended) ~~Use according to claim 2~~ The method of Claim 1,
wherein the ~~individuals described in point (b) display several of the~~
following subject is an individual with early symptoms of Parkinson's
disease, in whom at least three of the four cardinal symptoms of
Parkinson's disease (rigidity, resting tremors, bradykinesia, postural
instability) are not yet or are only partially present, said individual
displaying more than one clinical symptoms: symptom selected from the
group consisting of olfactory disorders, depression, sleep disorders of the
~~[[type]]~~ "REM behavior disorder" type, constipation and short-term
movement anomalies.
4. (Currently amended) ~~Use according to claim 2~~ The method of Claim 2,
wherein the ~~individuals display~~ subject displays a mutation in a PARK
gene and/or modifications to the alpha synuclein or neuromelanin pattern.
5. (Currently amended) ~~Use according to one of the preceding claims~~ The
method of Claim 1, wherein, in the formula for said compound, R3 and
R4 each represent hydrogen.
6. (Currently amended) ~~Use according to one of the preceding claims~~ The
method of Claim 1, wherein, in the formula for said compound, A is a
hydrogen atom or a group selected from



wherein R6 is C1-12 alkyl, phenyl or methoxyphenol.


7. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein, in the formula for said compound, n ~~[[=]]~~ is 1 to 3.
8. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein, in the formula for said compound, R1 is selected from the group



wherein X is S, O or NH.

9. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein, in the formula for said compound, X is a sulphur atom.
10. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein, in the formula for said compound, R5 is a C3 alkyl.
11. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein, in the formula for said compound, R1 is a 2-thienyl, R3 and R4 are both H, R5 is a C3 alkyl and n = 2.
12. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein the compound is 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]-amino]-1-naphthol.
13. (Currently amended) ~~Use according to claim 12~~ The method of Claim 12, wherein the compound is the pure S-enantiomer (rotigotine).
14. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein the ~~individuals display~~ subject displays a dopaminergic cell loss in the substantia nigra of less than 60% before commencement of ~~medicament~~ the administration.

15. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein the ~~individuals have~~ subject has a UPDRS score of less than 10 before commencement of ~~medicament~~ the administration.
16. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein the ~~individuals have~~ subject has a Hoehn-Yahr score of 0 or 1.
17. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein the ~~medicament is provided for parenteral, transdermal or mucosal administration~~ compound is administered parenterally, transdermally or mucosally.
18. (Currently amended) ~~Use according to one of the preceding claims~~ The method of Claim 1, wherein the compound ~~of general formula I~~ is administered in a dose of 0.05 to 50 mg per day.
19. (Currently amended) ~~Kit for the A kit for~~ diagnosis and treatment of Parkinson's disease, comprising
- (a) a diagnostic agent that enables ~~[[the]]~~ a diagnosis of Parkinson's disease and/or ~~[[the]]~~ a predisposition to develop Parkinson's disease at an early or asymptomatic stage; and
- (b) a pharmaceutical formulation comprising ~~substituted 2-aminotetralins of general formula I, as defined in one of claims 1 to 13~~ a compound of the general formula




wherein:

n = 1 to 5;

R2 is OA;

R3 and R4 are each independently selected from H and OA; with


A being selected from H, alkyl, alkoxymethyl or a group



wherein R6 and R7 are independently alkyl or aryl;

R5 is a C1-3 alkyl;

R1 is a group selected from hydrogen, 3-pyridyl, 4-pyridyl, optionally substituted phenyl,



wherein X is selected from S, O or NH;

wherein the compound is present as a racemate or as a pure (R)- or (S)-enantiomer; or a physiologically acceptable salt of said compound.

20. (Currently amended) ~~Kit according to claim 19~~ The kit of Claim 19,
wherein the diagnostic agent (a) ~~is selected from:~~ comprises
- (i) an agent or a diagnosis kit for detecting neuromelanin;
 - (ii) an agent or a diagnosis kit for detecting semaphorin 3;
 - (iii) an agent or a diagnosis kit for detecting alpha-synuclein and/or its aggregates; or
 - (iv) an agent or a diagnosis kit for genetically detecting a mutation associated with the appearance of Parkinson's disease and/or an allele associated with the more frequent appearance of Parkinson's disease.